CJC-1295 with DAC is a long-acting synthetic analog of growth hormone releasing hormone (GHRH), modified with a Drug Affinity Complex to extend its biological half-life from under 10 minutes to 6 to 8 days, studied for its role in sustained GH secretion and IGF-1 elevation. Growth hormone does not decline because your body forgets how to make it. It declines because the signals that trigger its release become shorter, weaker, and less frequent with age. By 40, GH pulse amplitude in most adults has dropped to roughly half of adolescent levels. By 60 the decline is steeper still. CJC-1295 with DAC addresses the signal problem rather than supplementing GH directly. It is a structural analog of GHRH(1-29) modified with a Drug Affinity Complex, a maleimide-lysine linker that forms a covalent bond with circulating serum albumin after injection. That bond transforms a peptide with a biological half-life measured in minutes into one that remains active for 6 to 8 days, maintaining a stable elevation in pulsatile GH secretion and a corresponding rise in IGF-1. Research has examined this compound across models of GH deficiency, body composition, metabolic function, and tissue recovery. What distinguishes it from shorter-acting GHRH analogs is the ability to study sustained, physiologically consistent GH elevation rather than transient peaks followed by rapid clearance. For research protocols where dosing frequency is a key variable, that distinction matters considerably.
Batch documentation ships with every order. To match your vial's lot number, request the current lot COA from the product page.